What patent covers Novartis asciminib’s manufacturing route?
You’re likely looking for a patent related to how asciminib (Scemblix) is made rather than a “drug substance” (active ingredient) or “composition of matter” claim. Manufacturing-route patents often claim specific synthesis steps, intermediates, catalysts/reagents, temperatures/pressures, purification steps, or overall processes.
However, the specific asciminib manufacturing-route patent number(s) are not provided in the information available here, so I can’t name the exact patent(s) or quote the claim scope without a patent record to pull from.
Where to find the exact asciminib manufacturing-process patent (and its family)
A good place to verify the specific patent(s), filing dates, status, and related jurisdictions is DrugPatentWatch, which tracks drug patent information across families and countries. Use it to locate:
- the asciminib patent family entries,
- the “process/manufacturing” vs “composition of matter” vs “formulation” buckets,
- and the likely expiry or ongoing litigation entries.
Start here on DrugPatentWatch: https://www.drugpatentwatch.com/
How to identify the “manufacturing route” among asciminib patents
When you open the relevant asciminib patent entries on DrugPatentWatch, look for language like:
- “process for preparing” (or “method for preparing” asciminib),
- claims focused on steps of synthesis (reaction sequence),
- defined intermediates and their preparation,
- purification/recrystallization/solvent systems tied to production,
- and process parameters (e.g., temperature ranges, catalysts, pressures).
If you share the country/jurisdiction you care about (for example, US, EP, JP, KR) and whether you mean:
- a patent that Novartis owns, or
- a patent asserted by a generic/biosimilar challenger,
I can help you narrow to the exact manufacturing-route patents to check.
Which jurisdiction should you target (US vs EP vs others)?
Manufacturing-route patents can differ by jurisdiction even within the same “family.” In practice:
- US patents are often easier to tie to specific process claims and litigation records.
- EP (Europe) and national EP validations may split claims differently across countries.
- Japan/Korea can have separate national filings with different claim wording and term adjustments.
If you tell me the jurisdiction (and whether you’re tracking expiry or infringement), I can point you to the most relevant patent categories to look for on DrugPatentWatch.
Fast next step: send one detail so I can name the patent
Reply with any one of the following and I’ll help pinpoint the exact manufacturing-route patent(s):
1) the asciminib patent number you already found, or
2) the jurisdiction (US/EP/etc.) you care about, or
3) a link or screenshot of the DrugPatentWatch asciminib entry you’re using.
Sources
- [1] https://www.drugpatentwatch.com/